help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fratta, P.
Right arrow Articles by Askanas, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fratta, P.
Right arrow Articles by Askanas, V.
(American Journal of Pathology. 2005;167:517-526.)
© 2005 American Society for Investigative Pathology

Proteasome Inhibition and Aggresome Formation in Sporadic Inclusion-Body Myositis and in Amyloid-ß Precursor Protein-Overexpressing Cultured Human Muscle Fibers

Pietro Fratta*, W. King Engel*, Janis McFerrin*, Kelvin J.A. Davies{dagger}, Sharon W. Lin{dagger} and Valerie Askanas*

From the Department of Neurology,* University of Southern California Neuromuscular Center, University of Southern California Keck School of Medicine, Good Samaritan Hospital, Los Angeles; and the Ethel Mercy Andrus Gerontology Center and Division of Molecular and Computational Biology,{dagger} University of Southern California, Los Angeles, California


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
The 26S proteasome system is involved in eliminating various proteins, including ubiquitinated misfolded/unfolded proteins, and its inhibition results in cellular accumulation of protein aggregates. Intramuscle-fiber ubiquitinated multiprotein-aggregates are char-acteristic of sporadic inclusion-body myositis (s-IBM) muscle fibers. Two major types of aggregates exist, containing either amyloid-ß (Aß) or phosphorylated tau (p-tau). We have now asked whether abnormalities of the 26S proteasome contribute to s-IBM pathogenesis and whether the multiprotein aggregates have features of aggresomes. Using cultured human muscle fibers we also studied the effect of amyloid-ß precursor protein (AßPP) overexpression on proteasome function and the influence of proteasome inhibition on aggresome formation. We report that in s-IBM muscle biopsies 26S proteasome subunits were immunodetected in the {gamma}-tubulin-associated aggresomes, which also contained Aß, p-tau, ubiquitin, and HSP70. In addition, a) expression of proteasome subunits was greatly increased, b) the 20S{alpha} proteasome subunit co-immunoprecipitated with AßPP/Aß, and c) the three major proteasomal proteolytic activities were reduced. In cultured muscle fibers, AßPP-overexpressing fibers displayed diminished proteasomal proteolytic activities, and addition of proteasome inhibitor strikingly increased aggresome formation. Accordingly, proteasome dysfunction in s-IBM muscle fibers may play a role in accumulation of misfolded, potentially cytotoxic proteins and may be induced by increased intracellular AßPP/Aß.

Sporadic inclusion body myositis (s-IBM), the most common degenerative muscle disease of patients age 50 years and older, is of unknown etiology and pathogenesis, and it lacks definitive treatment.1,2 The light-microscopic features of s-IBM muscle biopsies include: 1) vacuolated muscle fibers; 2) accumulation of intramuscle fiber multiprotein aggregates; and 3) various degrees of lymphocytic inflammation.1,2 An intriguing feature of the s-IBM muscle-fiber phenotype is its similarity to the Alzheimer’s disease (AD) brain, including accumulation of amyloid-ß (Aß), phosphorylated tau (p-tau), and several other Alzheimer-characteristic proteins.1,2 Two major types of intracellular aggregates contain either Aß or p-tau,1-4 and both contain ubiquitin.1,2 Both types of aggregates are positive with crystal-violet, thioflavin S, and Congo Red, indicating that they contain proteins in alternate conformation (unfolded or misfolded) that are assembled in the ß-pleated-sheet configuration of amyloid.1,2 Both types of aggregates contain several other accumulated proteins,1,2 including mutated ubiquitin (UBB+1)5 . Recently the unfolded protein response was demonstrated in s-IBM muscle fibers,6 further suggesting a role for misfolded/unfolded proteins in the s-IBM pathogenesis. Some of the proteins in those aggregates have been shown experimentally to inhibit the 26S proteasome.7-13

The 26S proteasome, composed of a catalytic 20S core and a 19S regulatory complex, is an ~700-kd multisubunit protease complex present in the cytoplasm and nucleus of eukaryotic cells. It plays a major role in the degradation of normal and abnormal proteins, through a ubiquitin-mediated ATP-independent process.14,15 19S mediates the recognition of polyubiquitinated proteins, permitting their access into the 20S component core, which is comprised of {alpha}- and ß-subunits. ß-Subunits contain trypsin-like (TL), chymotrypsin-like (CTL), and peptidyl-glutamyl-peptide hydrolytic (PGPH) activities.14,15 Three ß-subunits, ß1, ß2 and ß5, have {gamma}-interferon-inducible counterparts,14 which increase CTL and TL proteasome activities that are optimal for major histocompatibility complex-I (MHC-I) epitope processing.16,17 The 20S proteasome is involved also in ubiquitin-independent degradation of several proteins,18,19 and in degradation of oxidized proteins in an ATP-independent manner.20

Aggresomes, microtubule-dependent pericentriolar cytoplasmic structures, form when a cell’s capacity to degrade misfolded proteins is diminished.21,22 Their formation requires an intact microtubule system,21,22 and the presence of {gamma}-tubulin is their distinctive feature.21-23 Aggresomes contain multiubiquitinated misfolded proteins, and various other proteins, including heat-shock proteins (HSPs) and 20/26S proteasome components.22-24 In various mononucleated cells, aggresomes have been induced by overexpression of both normal and mutated proteins combined with proteasome inhibition.21-23,25,26 Recently, it has been suggested that Lewy bodies in Parkinson’s disease are related to aggresomes.27 Whether aggresomes contribute to cellular death or protect cells from toxic effects of misfolded proteins remains uncertain. We have now asked whether s-IBM muscle fiber multiprotein-aggregates have features of aggresomes and if proteasome inhibition may contribute to the s-IBM pathogenesis. These questions were further explored in our experimentally induced IBM model, which is based on genetic overexpression of amyloid-ß precursor protein (AßPP) in cultured human muscle fibers.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Muscle Biopsies

Immunocytochemical studies were performed on 10-µm-thick transverse sections of fresh-frozen diagnostic muscle biopsies obtained with informed consent from 25 patients with these diagnoses: 10 s-IBM, 3 polymyositis, 1 dermatomyositis, 2 morphologically nonspecific myopathy, 4 peripheral neuropathy, 2 amyotrophic lateral sclerosis, and 3 normal muscle. All IBM biopsies had muscle fibers with vacuoles on Engel trichrome staining,28 and 15- to 21-nm paired helical filaments (PHFs) by SMI-31 immunoreactivity4 and by electron microscopy, and Congo Red positivity using fluorescence enhancement.29

Light-Microscopic Immunocytochemistry

Immunocytochemistry was as described.3,4,6,30,31 We used 26 well-characterized monoclonal and polyclonal antibodies against 20S and 19S proteasome (Table 1) . Double immunofluorescence used selected antibodies against 20S and 19S proteasome in combination with one of the following: 1) mouse monoclonal antibody 6E10 (Signet, Dedham, MA), diluted 1:100, which morphologically recognizes Aß in both AD brain32 and s-IBM muscle,31 and on immunoblots it recognizes the Aß region within the parent AßPP molecule; 2) mouse monoclonal antibody SMI-31 (Sternberger Monoclonals, Inc., Baltimore, MD), diluted 1:1000, which recognizes p-tau of s-IBM4 and AD PHFs;33 3) AT100 antibody (Pierce Biotechnology, Rockford, IL), diluted 1:1000, which recognizes p-tau of AD PHFs.34 Aggresomes were identified by well-characterized mouse monoclonal and rabbit polyclonal antibodies against {gamma}-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA). This was combined with one of the following: 1) mouse monoclonal antibody against ubiquitin (Chemicon, Temecula, CA), diluted 1:100; 2) mouse monoclonal antibody 6E10; 3) mouse monoclonal antibody SMI-31; 4) rabbit polyclonal or mouse monoclonal antibodies against 20S and 19S proteasome subunits; and 5) rabbit polyclonal antibody against HSP70 (StressGene, Victoria, British Columbia) diluted 1:200. To block nonspecific binding of antibody to Fc receptors, sections were preincubated with normal goat or rabbit serum diluted 1:10, as described.3,34,35 Controls for staining specificity were omission of the primary antibody, or its replacement with nonimmune sera or irrelevant antibody.


View this table:
[in this window]
[in a new window]
  		Table 1. Intensities of Immunohistochemical Reactions Using Various Antibodies against 20S and 19S Proteasome Subunits in s-IBM Muscle Fibers

 
Immunoelectron Microscopy

Single- and double-label gold immunoelectron microscopy was performed on 10-µm unfixed frozen sections adhered to the bottom of 35-mm Petri dishes, as described.3,4,6,30,31 In brief, a primary antibody against the 20S or 19S proteasome subunit was used separately or in combination with each other, and an antibody against 20S proteasome was also combined with antibodies against Aß or p-tau. After incubation with the appropriate secondary antibodies conjugated to 5-nm and 10-nm gold particles, sections were processed for electron microscopy as described.4,6,30,31 The same procedure ultrastructurally immunolocalized {gamma}-tubulin.

Immunoblotting

Muscle biopsies of six s-IBM and six age-matched control patients were immunoblotted, as recently detailed.6,30 In brief, 10 µg of protein were loaded onto 10% NuPAGE gels (Invitrogen, Grand Island, NY), electrophoresed, transferred to nitrocellulose membranes, and immunoprobed with antibodies against 19S and 20S proteasome. After incubation in the appropriate secondary antibodies, blots were developed using an enhanced chemiluminescence system (Amersham Biosciences, Piscataway, NJ). Protein loading was evaluated by the Coomassie blue-stained myosin band. Quantification of immunoreactivity was performed by densitometric analysis using NIH Image J 1.310. One sample, designated as standard, was used on every gel so that band densities on different blots could be normalized to that standard,35 allowing comparison of protein samples on multiple blots.

Combined Immunoprecipitation/Immunoblot Procedure

To evaluate whether in s-IBM muscle fibers 20S proteasome physically associates with Aß/AßPP, a combined immunoprecipitation/immunoblot technique was performed, as we recently described in detail.6,30 In brief, 100 µg of total muscle protein from s-IBM and control biopsies were immunoprecipitated with 5 µg of 6E10 antibody, as described.6,30 Immunoprecipitates were separated by electrophoresis, transferred to a nitrocellulose membrane, and immunoblotted with 20S{alpha}4 subunit proteasome antibody, diluted 1:2000. Subsequently, an appropriate secondary antibody and Western Breeze anti-mouse chemiluminescence kit (Invitrogen) were used. To confirm the specificity of those experiments, the following controls were performed: the 6E10 antibody against AßPP/Aß, which was used for immunoprecipitation, was omitted, and the 20S{alpha}4 primary antibody used for immunoblotting of immunoprecipitates was omitted.

Measurement of Proteasome Activity

Three main proteasome activities were determined by evaluating the cleavage of specific fluorogenic substrates.20 Four s-IBM and four age-matched control muscle biopsies were homogenized in 20 mmol/L Tris-HCl, pH 7.2, containing 0.1 mmol/L ethylenediamine tetraacetic acid, 1 mmol/L 2-mercaptoethanol, 5 mmol/L ATP, 20% glycerol, and 0.04% (v/v) Nonidet P-40,36,37 centrifuged, the supernatant collected, and protein concentration determined using the Bradford method. Subsequently, 200 µg of biopsied muscle protein or 30 µg of protein from cultured muscle (see below), were incubated in 100 µmol/L fluorogenic substrates for the three different protease activities: Z-Leu-Leu-Glu-AMC (substrate II) for PGPH; Suc-Leu-Leu-Val-Tyr-AMC (substrate III) for CTL; and Z-Ala-Arg-Arg-AMC (substrate VI) for TL activity. Fluorescence emission was excited at 360 nm and recorded at 430 nm.37

Statistical Analysis

Statistical analyses were performed by a one-tailed t-test for both the proteasome activity and proteasome protein levels. Significance level was set at P < 0.05. Data are reported as means ± SEM for all groups.

Cultured Human Muscle Fibers

Tissue cultures of normal human muscle were established from satellite cells of portions of diagnostic muscle biopsies from patients who, after all tests were performed, were considered free of muscle disease.38 In five experimental culture sets, each established from a different muscle biopsy, a 3-kb 751 AßPP-cDNA, in sense or in anti-sense orientation, was transferred into 3-week-old cultured muscle fibers using an adenovirus vector, doses as described.39,40 Three days after the transfer, experimental and control (non-AßPP-overexpressing) cultures were treated with 1 µmol/L epoxomicin (Biomol Research Laboratories, Plymouth Meeting, PA), an irreversible proteasome inhibitor,36 and after 24 hours they were processed for light- and electron-microscopic immunocytochemistry, as described.40 At the same time, cultures were harvested for measurements of proteasome activity. Selected cultures were also treated, concurrently with epoxomicin, with 1 µmol/L of microtubule-disruptor nocodazole (Sigma, St. Louis, MO), which has been shown to disrupt aggresome formation.21


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
s-IBM and Control Muscle Biopsies

Light-Microscopic Immunocytochemistry

In all s-IBM muscle biopsies, 70 to 80% of the vacuolated muscle fibers contained, mainly in their nonvacuolated cytoplasm, numerous well-defined, plaque-like, dotty or elongated aggregates immunoreactive with antibodies against 20S and 19S proteasome subunits. In addition, in all biopsies, 20 to 30% of the nonvacuolated, otherwise normal-appearing fibers (on a given cross-section) contained similar aggregates (Figure 1; A to F, J, M, P) . By double-label immunofluorescence, in all abnormal muscle fibers, aggregates immunoreactive for 20S and 19S proteasome co-localized with each other (Figure 1; D to F) and with Aß or p-tau immunoreactivity (Figure 1; G to R) . Both anti-p-tau antibodies used gave the same results. Immunoreactivity with the 26 antibodies directed against various proteasome subunits is presented in Table 1 .



View larger version (78K):
[in this window]
[in a new window]
  		Figure 1. Immunofluorescence of 26S proteasome subunits in s-IBM muscle. A–C: Single-label immunofluorescence illustrates strongly immunoreactive, various-sized aggregates of Ps20S{alpha} (A), Ps20Sß1 constitutive (B), and Ps20Sß1I (inducible LMP2 subunit) (C) in s-IBM abnormal muscle fibers. D–S: Double-label immunofluorescence illustrates that in s-IBM muscle fibers the aggregates immunoreactive for Ps20S (D) are also immunoreactive for Ps19S (D–F merged), and both Ps20S (G, J)- and Ps19S (M, P)-immunoreactive aggregates are immunoreactive for amyloid-ß (H and I merged, N and O merged) and for p-tau (K, Q, and S merged). Original magnifications, x1100.

 
Accumulated aggregates had several features of aggresomes, because 70 to 80% of them were associated with {gamma}-tubulin and they contained ubiquitin and HSP70, in addition to Aß and p-tau (Figure 2) . In contrast to classical aggresomes originally described in mononucleated cells,21,22 aggresomes in s-IBM muscle fibers did not have perinuclear localization (Figure 2; P to S) . None of the control non-s-IBM, diseased and normal, human muscle biopsies had muscle fibers containing aggregates immunoreactive with antibodies against 20S, 19S, or {gamma}-tubulin. Eliminating primary antibodies or replacing them with nonrelevant antibodies resulted in nonstaining.



View larger version (76K):
[in this window]
[in a new window]
  		Figure 2. Double-label immunofluorescence of {gamma}-tubulin with Aß, 20S PS, HSP70, p-tau, and ubiquitin (UB), indicating aggresomes in s-IBM muscle fibers. P to S illustrate that {gamma}-tubulin-immunoreactive aggregates are not associated with the nuclei marked by the blue nuclei marker Hoechst. Original magnifications, x1100.

 
Immunoelectron Microscopy

In s-IBM abnormal muscle fibers, double immunolabeling of both 20S and 19S proteasome revealed that both subunits were associated with the same structures, namely PHFs, 6- to 10-nm amyloid-like fibrils, and floccular material (Figure 3, A and B) . Because both the 20S and 19S proteasome subunits localized to the same structures, electron microscopic double immunolabeling with Aß and p-tau was performed only with the antibody against 20S. This revealed that 20S was associated with both Aß on 6- to 10-nm amyloid-like fibrils and floccular material (Figure 3C) and p-tau on PHFs (Figure 3D) . In contrast to p-tau, which was localized on PHFs themselves, the proteasome subunits were in small clusters adjacent to PHFs but not directly on them (Figure 3D) . {gamma}-Tubulin was associated with PHFs (Figure 3E) , and together with Aß it was associated with 6- to 10-nm fibrils (Figure 3F) .



View larger version (182K):
[in this window]
[in a new window]
  		Figure 3. Double-label gold immunoelectron microscopy in s-IBM (A–F) and AßPP-overexpressing cultured muscle fibers (G). Ps20S (5-nm gold particles) and Ps19S (10-nm gold particles) are both associated with PHFs (A), and 6- to 10-nm amyloid-like fibrils and floccular amorphous material (B). Ps20S (5-nm gold particles) and amyloid-ß (10-nm gold particles) are both associated on 6- to 10-nm amyloid-like fibrils and floccular amorphous material (C). Ps20S (5-nm gold particles) and p-tau (10-nm gold particles) are both associated with PHFs (D), but in contrast to p-tau, which is localized on the filaments themselves, Ps20S is in small clusters adjacent to PHFs but not directly on them (D). E and F: {gamma}-Tubulin. E: Single label showing association of {gamma}-tubulin with PHFs. F: Double immunolocalization of {gamma}-tubulin (5-nm gold particles) with Aß (10-nm gold particles) shows that both are associated with 6- to 10-nm fibrils and amorphous material. G: Double immunolocalization of {gamma}-tubulin (5-nm gold particles) with Aß (10-nm gold particles) in an AßPP-overexpressing plus epoxomicin-treated cultured human muscle fiber. Similar to biopsied s-IBM muscle fibers, both {gamma}-tubulin (5-nm gold particles) and Aß (10-nm gold particles) are associated with 6- to 10-nm fibrils. Original magnifications: x48,500 (A–C, E–G); x61,400 (D).

 
Immunoblots of Proteasome Subunits

In s-IBM and normal muscle biopsies, the 20S {alpha}- and ß-subunits each migrated as either single or double bands of ~28 kd, whereas the 19S Rpn10 subunit migrated as a 45-kd band, in the typical positions for each. Expression of subunits 20S{alpha}4, 20Sß1, ß2 and ß5, and of 19S Rpn10 was increased in s-IBM muscle biopsies as compared to control biopsies (Figure 4, A and C) . Omitting the primary antibody resulted in nonstaining (Figure 4A) .



View larger version (32K):
[in this window]
[in a new window]
  		Figure 4. Immunoblots of 26S proteasome subunits and immunoprecipitation in control and s-IBM muscle biopsies. A: Immunoblots of muscle homogenates of normal control and s-IBM muscle biopsies demonstrate in s-IBM a much stronger expression of Ps 19S, Ps 20S{alpha}4, and Ps 20Sß2 subunits as compared to control muscle biopsies. Omission of primary antibodies resulted in negative reactions. B: Densitometric analysis of the blots in A, performed using NIH Image J 1.310. Protein loading was evaluated by the Coomassie blue-stained myosin band. One sample, designated as standard, was used on every gel so that band densities on different blots could be normalized to this standard. Data are indicated as mean ± SE. Significance was determined by one-tailed unpaired t-test. The level of significance was set at P < 0.05. C: Immunoblots of the constitutive ß1 and ß5, and the inducible LMP2 and LMP7, subunits in control and s-IBM muscle biopsies illustrate increased expression of both ß1 and ß5 in s-IBM as compared to controls: LMP2 and LMP7 subunits are present in s-IBM but are not detectable in controls. D: Immunoprecipitations of control and s-IBM biopsies with 6E10 antibody against AßPP/Aß, followed by immunoprobing with an antibody against 20S{alpha}4 proteasome subunit. A strong band of the appropriate molecular weight corresponding to the 20S{alpha} proteasome subunit is revealed in s-IBM muscle, whereas the control has only a very weak band (1). Omission of the antibody against 20S{alpha} (2) or omission of the antibody against AßPP/Aß (3) resulted in negative reactions.

 
In six s-IBM muscle biopsies, densitometry of 20S proteasome subunits {alpha}4 and ß2, and of 19S subunit Rpn10, evaluated after normalization to the corresponding myosin band, revealed, as compared to the six age-matched control muscle biopsies, that {alpha}4 was increased 5.6 times (P < 0.01), ß2 was increased 5.9 times (P < 0.01), and 19S was increased 2.4 times (P < 0.02) (Figure 4B) . In addition, LMP2 and LMP7, inducible counterpart subunits, respectively, of ß1 and ß5, were strongly expressed in s-IBM muscle but were virtually undetectable in control muscle biopsies (Figure 5C) .



View larger version (44K):
[in this window]
[in a new window]
  		Figure 5. Proteasome enzymatic activities in control and s-IBM muscle biopsies (A), and in cultured control and AßPP-overexpressing (AßPP+), and in not-AßPP-overexpressing but epoxomicin-treated human muscle fibers (B). A: Proteasome TL, CTL, and PGPH activities were measured in four s-IBM and four normal control muscle biopsies and results were normalized to proteasome quantity in the same muscle biopsies. All three proteasome activities are significantly reduced in s-IBM muscle biopsies, CTL to 29.4% (P < 0.02), TL to 53.5% (P < 0.04), and PGPH to 14.5% (P < 0.02) of control muscle biopsies. Data are indicated as mean ± SE. Significance was determined by the one-tailed unpaired t-test. The level of significance was set at P < 0.05. B: TL, CTL, and PGPH activities were measured in five sets of normal cultured human muscle fibers having AßPP-overexpression (AßPP+), in their not-AßPP-overexpressing cultured sister controls, and in not-AßPP+ epoxomicin-treated cultures. The results were normalized to proteasome quantity. In AßPP+ cultures, TL and PGPH activities are reduced to 55.8% and to 85.4% of controls, respectively, with no significant change in CTL. Data are indicated as mean ± SE. Epoxomicin treatment reduced CTL, TL, and PGPH to 16.0%, 69.1%, and 33.4% of controls, respectively.

 
Immunoprecipitation

Immunoprecipitation of s-IBM and control muscle biopsies with mouse monoclonal 6E10 antibody, which recognizes either Aß or AßPP, followed by immunoprobing with a mouse monoclonal antibody against 20S, revealed a very strong 20S proteasome band of 28 kd in s-IBM muscle, but only an extremely weak band in control muscle (Figure 4D) . Omitting of either the 6E10 antibody used for immunoprecipitation or the primary antibody used for immunoprobing gave negative results.

Proteasome Activity

20S proteasome activities were measured in the same s-IBM and normal control muscle biopsies in which immunoblots were performed, and their activities were normalized to the 20Sß2 proteasome protein value measured in each patient.35 In s-IBM biopsies, CTL, TL, and PGPH protease activities were reduced to 29.4% (P < 0.02), 53.5% (P < 0.04), and 14.5% (P < 0.02), respectively, as compared to the control biopsies (Figure 5A) .

Cultured Muscle Fibers

Light-Microscopic Immunocytochemistry

In all five experimental sets of human cultured muscle fibers, overexpression of AßPP, combined with epoxomicin treatment, induced in the cytoplasm of 85 to 95% of cultured muscle fibers numerous well-defined, various-sized, round, or dotty {gamma}-tubulin-immunoreactive aggregates, which by double-label immunofluorescence were also immunoreactive for Aß, ubiquitin, HSP70, and proteasome subunits (Figure 6; A to J) . Approximately 20% of the control, non-AßPP-overexpressing but epoxomicin-treated cultured muscle fibers had only very small {gamma}-tubulin-immunoreactive aggregates (not shown). AßPP-overexpressing, but not epoxomicin-treated, cultured fibers had well-defined, various-sized {gamma}-tubulin- and Aß-immunoreactive aggregates in ~40% of fibers (Figure 6, K and L) . As in a previous study,21 nocodazole prevented {gamma}-tubulin-immunoreactive aggregates in the majority of the fibers.



View larger version (38K):
[in this window]
[in a new window]
  		Figure 6. Double-label immunofluorescence of {gamma}-tubulin with Aß (A, B), 20S PS (C, D), HSP70 (E, F), and ubiquitin (UB) (G, H), indicating various-sized aggresomes in cultured human muscle fibers, that were AßPP-overexpressing plus epoxomicin-treated (A–J), and in ones AßPP-overexpressing but not treated with epoxomicin (K, L). J illustrates that most of the {gamma}-tubulin-immunoreactive aggregates are not associated with nuclei, which are indicated with the blue nuclei marker Hoechst. Original magnifications, x1400.

 
Immunoelectron Microscopy of Cultured Human Muscle Fibers

In AßPP-overexpressing plus epoxomicin-treated cultured human muscle fibers, both {gamma}-tubulin and Aß were associated with 6- to 10-nm amyloid-like fibrils (Figure 3F) .

Proteasome Activity

In AßPP-overexpressing cultured muscle fibers, after normalization to the 20Sß2 proteasome level, TL activity was reduced to 55.8% (P < 0.005), and PGPH to 85.4% (P < 0.04), as compared to control cultured muscle fibers, while there was no significant change in CTL activity (Figure 5) . Cultured muscle overexpressing anti-sense AßPP had no reduction of any proteolytic activity (data not shown). A 24-hour treatment with epoxomicin of non-Aß-overexpressing cultures reduced the CTL activity to 16%, TL to 69.1%, and PGPH to 33.4% (P < 0.01) of control (Figure 5B) .


   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
In this study we found significant proteasomal abnormalities in s-IBM muscle fibers as evidenced by: 1) abnormal accumulation of 26S proteasome subunits by immunofluorescence and immunoelectron microscopy; 2) increased expression of 26S proteasome subunits by immunoblots; and 3) reduced activities of the three major proteasomal proteolytic enzymes. Previously, in s-IBM muscle biopsies, abnormal proteasomal accumulations were reported, but their relationship to Aß/AßPP was not studied.41 Our present study strongly suggests that the AßPP/Aß-proteasome interrelationship may be important in inducing proteasome abnormalities and aggresome formation in s-IBM muscle fibers because: 1) Aß and proteasome co-localized at the light-microscopy level and were associated ultrastructurally with the same structures; 2) there was a physical association of Aß/AßPP and proteasome by immunoprecipitation studies; and 3) proteasome activity was inhibited in cultured human muscle fibers overexpressing Aß/AßPP.

In s-IBM muscle fibers, increased synthesis of AßPP1,2 is associated with its abnormal processing1,2 and with accumulation of its cytotoxic fragment Aß.1,2 Experimental overexpression of AßPP/Aß in cultured human muscle fibers was demonstrated to induce in them aspects of the IBM phenotype.1,2,39,40 Accordingly, it was proposed that overproduction of AßPP/Aß plays an important role in s-IBM pathogenesis.1,2 The inhibition of two major proteasome activities, TL and PGPH, by the overexpressed AßPP/Aß that we have demonstrated in the cultured muscle fibers suggests that AßPP/Aß may be causatively involved in proteasome inhibition in s-IBM fibers. Other factors present in s-IBM muscle fibers that might contribute to inhibition of proteasome function include: an aging muscle environment (because s-IBM patients are usually age 50 or older), protein over-crowding, oxidative stress,1,2 and accumulated p-tau,1,2,4 {alpha}-synuclein,31 and UBB+1 5, all shown to be capable of inhibiting proteasome activity.8-13 Abnormal proteasome distribution or its inhibition were suggested to contribute to the pathogenesis of several neurodegenerative diseases, including AD, Parkinson’s disease, Lewy-body dementia, and Huntington disease.9,15,42-44

Our demonstrated increase of proteasome-protein subunits may represent the muscle fiber’s attempt to deal with multiprotein overcrowding, but, in the presence of the severely impaired proteasomal enzymatic function those attempts are futile and the unfolded/misfolded proteins accumulate in the form of aggregates. Our study also demonstrated that most s-IBM multiprotein aggregates have some features of aggresomes, because they are associated with {gamma}-tubulin, and contain proteasome subunits, ubiquitin and HSP70. We also induced aggresome-like structures in cultured human muscle fibers by overexpressing AßPP, +/– epoxomicin treatment. Previously, aggresomes have been produced only in cultured mononucleated cells, where they appeared as perinuclear inclusions.21-24 However, in our studies, both in the s-IBM biopsied muscle fibers and in the AßPP-overexpressing cultured muscle fibers, aggresome-like structures were not associated with the nuclei. This might be related to the fact that a muscle fiber is a multinucleated cell and mechanisms responsible for the location of aggresomes might be different from in a mononucleated cell. Our study was not able to demonstrate a protective influence of aggresomes, which was reported in other cell systems.26 Even though the exact role of aggresome-like structures in s-IBM muscle fibers still needs to be investigated, their presence there, as well as their induction in cultured human muscle fibers by AßPP overexpression and proteasome inhibition, further support the prominent role of proteasome inhibition, and protein aggregation and misfolding, in the complex cascade of the s-IBM pathogenesis.

Proteasome is responsible for degradation of most cellular proteins.14,15 A failure to degrade/remove surplus proteins, including abnormal damaged proteins, would be detrimental to the muscle fiber. Furthermore, accumulated ubiquitinated, misfolded, and oxidized protein aggregates themselves can cause inhibition of proteasome.25,45 Also, the still soluble, early intermediates of protein aggregates, in the form of dimers and trimers, are highly toxic to cells,46,47 and they can also induce proteasome inhibition.11 Because proteasome inhibition might, in turn, contribute to the formation of soluble toxic protein oligomers, in a vicious circle, proteasome inhibition may be detrimental to the cells even before protein aggregates can be identified morphologically.

In addition to the formation of multiprotein aggregates, proteasome abnormalities might play another role in the s-IBM pathogenesis, namely the cytotoxic T-cell inflammation. Some s-IBM muscle fibers express MHC-I,48 which probably plays a role in the CD8+ cytotoxic T-cell response49 by enabling a muscle fiber to become antigen-presenting. Proteasomal inducible ß-subunits, LMP2 and LMP7, which we have shown increased in s-IBM muscle fibers, are involved in the intracellular processing of peptides for MHC-I expression.16,17 Possibly, in s-IBM muscle fibers LMP2 and LMP7 are involved in antigen presentation development of the T-cell inflammatory response.

In summary, our present study demonstrates proteasome dysfunction in s-IBM muscle fibers, and it suggests that Aß/AßPP may promote that dysfunction. Our studies raise the possibility of novel therapeutic manipulations to correct that proteasomal malfunction.


   Acknowledgements
 
We thank Maggie Baburyan for providing excellent technical assistance in electron microscopy.


   Footnotes
 
Address reprint requests to Valerie Askanas, M.D., Ph.D., USC Neuromuscular Center, Good Samaritan Hospital, 637 S. Lucas Ave., Los Angeles, CA 90017-1912. E-mail: askanas{at}hsc.usc.edu

Supported by grants (to V.A.) from the National Institutes of Health (AG16768 merit award), the Muscular Dystrophy Association, the Myositis Association, and the Helen Lewis Research Fund.

Accepted for publication April 21, 2005.


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

  1. Askanas V, Engel WK: Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003, 15:737-744[Medline]
  2. Askanas V, Engel WK: Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease. J Neuropathol Exp Neurol 2001, 60:1-14[Medline]
  3. Askanas V, Alvarez RB, Engel WK: Beta-amyloid precursor epitopes in muscle fibers of inclusion body myositis. Ann Neurol 1993, 34:551-560[Medline]
  4. Askanas V, Alvarez RB, Mirabella M, Engel WK: Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis. Ann Neurol 1996, 39:389-391[Medline]
  5. Fratta P, Engel W, Van Leeuwen F, Hol E, Vattemi G, Askanas V: Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers. Neurology 2004, 63:1114-1117[Abstract/Free Full Text]
  6. Vattemi G, Engel WK, McFerrin J, Askanas V: Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol 2004, 164:1-7[Abstract/Free Full Text]
  7. Borden KL: Structure/function in neuroprotection and apoptosis. Ann Neurol 1998, 44(Suppl 1):S65-S71
  8. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D: Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 1995, 270:19702-19708[Abstract/Free Full Text]
  9. Keck S, Nitsch R, Grune T, Ullrich O: Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease. J Neurochem 2003, 85:115-122[Medline]
  10. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ, Layfield R: Inhibition of the ubiquitin-proteasome system in Alzheimer’s disease. Proc Natl Acad Sci USA 2000, 97:9902-9906[Abstract/Free Full Text]
  11. Lindersson E, Beedholm R, Hojrup P, Moos T, Gai W, Hendil KB, Jensen PH: Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem 2004, 279:12924-12934[Abstract/Free Full Text]
  12. Lindsten K, de Vrij FM, Verhoef LG, Fischer DF, van Leeuwen FW, Hol EM, Masucci MG, Dantuma NP: Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation. J Cell Biol 2002, 157:417-427[Abstract/Free Full Text]
  13. Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E: Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 2003, 180:131-143[Medline]
  14. Voges D, Zwickl P, Baumeister W: The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 1999, 68:1015-1068[Medline]
  15. Sherman MY, Goldberg AL: Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29:15-32[Medline]
  16. Kloetzel PM: Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001, 2:179-187[Medline]
  17. Rock KL, York IA, Saric T, Goldberg AL: Protein degradation and the generation of MHC class I-presented peptides. Adv Immunol 2002, 80:1-70[Medline]
  18. Benaroudj N, Tarcsa E, Cascio P, Goldberg AL: The unfolding of substrates and ubiquitin-independent protein degradation by proteasomes. Biochimie 2001, 83:311-318[Medline]
  19. Jariel-Encontre I, Pariat M, Martin F, Carillo S, Salvat C, Piechaczyk M: Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome. J Biol Chem 1995, 270:11623-11627[Abstract/Free Full Text]
  20. Shringarpure R, Grune T, Mehlhase J, Davies KJ: Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 2003, 278:311-318[Abstract/Free Full Text]
  21. Johnston JA, Ward CL, Kopito RR: Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998, 143:1883-1898[Abstract/Free Full Text]
  22. Kopito RR: Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000, 10:524-530[Medline]
  23. Wigley WC, Fabunmi RP, Lee MG, Marino CR, Muallem S, DeMartino GN, Thomas PJ: Dynamic association of proteasomal machinery with the centrosome. J Cell Biol 1999, 145:481-490[Abstract/Free Full Text]
  24. Garcia-Mata R, Gao YS, Sztul E: Hassles with taking out the garbage: aggravating aggresomes. Traffic 2002, 3:388-396[Medline]
  25. Junn E, Lee SS, Suhr UT, Mouradian MM: Parkin accumulation in aggresomes due to proteasome impairment. J Biol Chem 2002, 277:47870-47877[Abstract/Free Full Text]
  26. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM: Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004, 279:4625-4631[Abstract/Free Full Text]
  27. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW: Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 2002, 16:2136-2148[Medline]
  28. Engel WK, Cunningham GG: Rapid examination of muscle tissue and improved trichrome method for fresh-frozen biopsy sections. Neurology 1963, 13:919-923
  29. Askanas V, Engel WK, Alvarez RB: Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer’s disease using fluorescence technique. Neurology 1993, 43:1265-1267
  30. Vattemi G, Engel WK, McFerrin J, Askanas V: Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloid-beta precursor protein in sporadic inclusion-body myositis muscles. J Neurochem 2003, 85:1539-1546[Medline]
  31. Askanas V, Engel WK, Alvarez RB, McFerrin J, Broccolini A: Novel immunolocalization of alpha-synuclein in human muscle of inclusion-body myositis, regenerating and necrotic muscle fibers, and at neuromuscular junctions. J Neuropathol Exp Neurol 2000, 59:592-598[Medline]
  32. Kim KS, Wen GY, Bancher C, Chen J, Sapienza V, Hong H, Wisniewski HM: Detection and quantitation of amyloid B-peptide with 2 monoclonal antibodies. Neurosci Res Commun 1990, 7:113-122
  33. Nukina N, Kosik KS, Selkoe DJ: Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein. Proc Natl Acad Sci USA 1987, 84:3415-3419[Abstract/Free Full Text]
  34. Zheng-Fischhèofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow E: Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem 1998, 252:542-552[Medline]
  35. Husom AD, Peters EA, Kolling EA, Fugere NA, Thompson LV, Ferrington DA: Altered proteasome function and subunit composition in aged muscle. Arch Biochem Biophys 2004, 421:67-76[Medline]
  36. Meng L, Mohan R, Kwok B, Elofsson M, Sin N, Crews C: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999, 96:10403-10408[Abstract/Free Full Text]
  37. Demasi M, Shringarpure R, Davies KJ: Glutathiolation of the proteasome is enhanced by proteolytic inhibitors. Arch Biochem Biophys 2001, 389:254-263[Medline]
  38. Askanas V, Engel WK: Cultured normal and genetically abnormal human muscle. The Handbook of Clinical Neurology, Myopathies, Vol 18. Edited by Rowland LP, Di Mauro S. Amsterdam, North Holland, 1992, pp 85–116
  39. Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi E, Engel WK: Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci USA 1996, 93:1314-1319[Abstract/Free Full Text]
  40. Askanas V, McFerrin J, Alvarez RB, Baque S, Engel WK: Beta APP gene transfer into cultured human muscle induces inclusion-body myositis aspects. Neuroreport 1997, 8:2155-2158[Medline]
  41. Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M: Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004, 63:484-498[Medline]
  42. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW: Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol 2003, 179:38-46[Medline]
  43. Schmidt T, Lindenberg KS, Krebs A, Schèols L, Laccone F, Herms J, Rechsteiner M, Riess O, Landwehrmeyer GB: Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann Neurol 2002, 51:302-310[Medline]
  44. Keller JN, Hanni KB, Markesbery WR: Impaired proteasome function in Alzheimer’s disease. J Neurochem 2000, 75:436-439[Medline]
  45. Bence NF, Roopal MS, Kopito RS: Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292:1552-1555[Abstract/Free Full Text]
  46. Klein WL: ADDLs & protofibrils—the missing links? Neurobiol Aging 2002, 23:231-235[Medline]
  47. Ellis RJ, Pinheiro TJ: Medicine: danger—misfolding proteins. Nature 2002, 416:483-484[Medline]
  48. Dalakas MC: The molecular and cellular pathology of inflammatory muscle diseases. Curr Opin Pharmacol 2001, 1:300-306[Medline]
  49. Murata K, Dalakas MC: Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 1999, 155:453-460[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Nizzari, V. Venezia, E. Repetto, V. Caorsi, R. Magrassi, M. C. Gagliani, P. Carlo, T. Florio, G. Schettini, C. Tacchetti, et al.
Amyloid Precursor Protein and Presenilin1 Interact with the Adaptor GRB2 and Modulate ERK 1,2 Signaling
J. Biol. Chem., May 4, 2007; 282(18): 13833 - 13844.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
C. C. Weihl, S. E. Miller, P. I. Hanson, and A. Pestronk
Transgenic expression of inclusion body myopathy associated mutant p97/VCP causes weakness and ubiquitinated protein inclusions in mice
Hum. Mol. Genet., April 15, 2007; 16(8): 919 - 928.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
M. H. Helfrich, J. C. Crockett, L. J. Hocking, and F. P. Coxon
The Pathogenesis of Osteoclast Diseases: Some Knowns, but Still Many Unknowns
IBMS BoneKEy, February 1, 2007; 4(2): 61 - 77.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. F. Monis, C. Schultz, R. Ren, J. Eberhard, C. Costello, L. Connors, M. Skinner, and V. Trinkaus-Randall
Role of Endocytic Inhibitory Drugs on Internalization of Amyloidogenic Light Chains by Cardiac Fibroblasts
Am. J. Pathol., December 1, 2006; 169(6): 1939 - 1952.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, and L. Neckers
Endoplasmic Reticulum Vacuolization and Valosin-Containing Protein Relocalization Result from Simultaneous Hsp90 Inhibition by Geldanamycin and Proteasome Inhibition by Velcade
Mol. Cancer Res., September 1, 2006; 4(9): 667 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Kitazawa, K. N. Green, A. Caccamo, and F. M. LaFerla
Genetically Augmenting A{beta}42 Levels in Skeletal Muscle Exacerbates Inclusion Body Myositis-Like Pathology and Motor Deficits in Transgenic Mice
Am. J. Pathol., June 1, 2006; 168(6): 1986 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. M. Rosen, V. Veereshwarayya, C. E-H. Moussa, Q. Fu, M. S. Goldberg, M. G. Schlossmacher, J. Shen, and H. W. Querfurth
Parkin Protects against Mitochondrial Toxins and beta-Amyloid Accumulation in Skeletal Muscle Cells
J. Biol. Chem., May 5, 2006; 281(18): 12809 - 12816.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
V. Askanas and W. K. Engel
Inclusion-body myositis: A myodegenerative conformational disorder associated with A{beta}, protein misfolding, and proteasome inhibition
Neurology, January 24, 2006; 66(1_suppl_1): S39 - S48.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fratta, P.
Right arrow Articles by Askanas, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fratta, P.
Right arrow Articles by Askanas, V.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS